Multiple abstracts on whole prostate gland and focal HIFU presented at World Congress of Endourology and Lithotripsy Two HIFU studies presented at Société Internationale d'Urologie Company highlights Technology as exhibiting sponsor at Five Major American Urological Association Section Meetings

Clearance of Predicate HIFU Technology for Ablation of Prostatic Tissue Permits Streamlined 510(k) Pathway

Live Focal One HIFU treatment at Robotic Urology Congress , Bilbao, Spain Strong participation in German Urology Society Congress Dedicated Intensive training program being implemented following purchase of Focal One by private group of Hospitals in France LYON, France , Sept.

LYON, France , Sept. 2, 2015 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that Marc Oczachowski , Chief Executive Officer of EDAP TMS is scheduled to present at the 17 th Annual Rodman & Renshaw Global Investment conference being held

Second quarter 2015 revenue increased 39% year-over-year to EUR 7.8 million ( USD 8.7 million ) Second Quarter 2015 HIFU revenues increased 55% year-over-year Strong and increased cash position at €11.8 Million on June 30, 2015 . Formal complete response to recent FDA Letter submitted on Friday,

FDA De Novo 510(k) Review of Prostatic Tissue Ablation Device to Resume

Conference Call and Webcast Scheduled for 8:30 a.m. ET

LYON, France , July 21, 2015 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that it has received a letter from the U.S. Food and Drug Administration ("FDA") related to its Direct De Novo 510(k) petition for Ablatherm HIFU in the United

10-year EDAP Finance Manager to Succeed Eric Soyer

Growing Interest in Europe for HIFU Focal Approach in the Management of Prostate Cancer